Cancer Risk Screening Tests That Help Early Detection
From PSA and CA-125 to CEA and AFP – understand which tumour-marker blood tests are included in private health screens and what they can (and cannot) tell you.
Key Takeaway
For several common cancers, five-year survival rates are significantly higher when diagnosed at an early stage (Cancer Research UK, 2024). Blood-based tumour markers do not diagnose cancer on their own, but elevated levels may prompt further investigation, including imaging and specialist referral where appropriate.
In This Article
- • What are tumour markers?
- • Key tumour markers used in private screening
- • What tumour markers can and cannot do
- • Who benefits most from cancer-risk screening?
- • NHS cancer screening vs private panels
- • What happens if a marker is elevated?
- • FAQs
What Are Tumour Markers?
Tumour markers are substances – usually proteins – produced by cancer cells or by the body in response to cancer. They circulate in the blood and can be measured with a standard venous blood draw.
It is important to note that elevated tumour markers do not confirm cancer. Benign conditions, inflammation, infection and even vigorous exercise can raise certain markers. Equally, some cancers do not elevate any marker at all. That is why tumour-marker results are always interpreted alongside clinical history, imaging and, where necessary, biopsy.
For a broader look at how blood tests identify cancer-related signals, see our article on early warning signs of cancer and how regular screening can help.
Key Tumour Markers in Private Screening
| Marker | Primary Association | Normal Reference | Non-Cancer Causes of Elevation |
|---|---|---|---|
| PSA | Prostate cancer | < 3 ng/mL (age-adjusted) | BPH, prostatitis, recent ejaculation, cycling |
| CA-125 | Ovarian cancer | < 35 U/mL | Endometriosis, fibroids, menstruation, peritonitis |
| CEA | Colorectal, lung, breast | < 5 ng/mL | Smoking, IBD, liver cirrhosis |
| AFP | Liver, testicular (germ cell) | < 10 ng/mL | Hepatitis, cirrhosis, pregnancy |
| CA 19-9 | Pancreatic, biliary | < 37 U/mL | Pancreatitis, bile duct obstruction, cholangitis |
Our companion article on whether cancer can be identified with a blood test explores the science behind these markers in more detail.
What Tumour Markers Can and Cannot Do
✓ They Can
- Flag elevated risk that prompts further investigation
- Provide a baseline for trend monitoring over time
- Assist in monitoring known cancers during treatment
- Detect recurrence after treatment in some cancers
✗ They Cannot
- Diagnose cancer on their own
- Replace imaging (CT, MRI, ultrasound) or biopsy
- Detect every type of cancer
- Guarantee a cancer-free result if levels are normal
This is why responsible screening clinics always present tumour-marker results within the context of a full health assessment. For more on understanding what screening reveals, see why cancer screening is crucial even if you feel perfectly healthy.
Who Benefits Most from Cancer-Risk Screening?
- Family history: First-degree relative diagnosed with cancer under 50
- Age 40+: Incidence of many cancers rises significantly after 40 – our guide to full-body health MOT tests by age covers what to screen for in your 30s, 40s and 50s
- Lifestyle risk factors: Smoking, high alcohol intake, obesity, sedentary behaviour
- Occupational exposure: Asbestos, benzene, radiation, shift work (classified as a probable carcinogen by IARC)
- Previous abnormal results: Earlier borderline markers warrant closer follow-up
Our guide to cancer screening tests included in health checkups details which markers are typically bundled into standard packages.
NHS Cancer Screening vs Private Panels
| Feature | NHS Screening Programmes | Private Tumour-Marker Panel |
|---|---|---|
| Cancers covered | Breast, cervical, bowel (specific age bands) | Multiple markers – prostate, ovarian, liver, colorectal, pancreatic |
| Eligibility | Fixed age/sex criteria | Any adult at any time |
| Test type | Imaging + stool (FIT) | Blood-based tumour markers ± imaging add-ons |
| Turnaround | 2–6 weeks | 24–72 hours |
| Doctor review | Letter or GP follow-up | Dedicated consultation with GMC-registered doctor |
Private panels complement – but do not replace – NHS programmes. Participation in bowel, breast and cervical screening remains essential. For a side-by-side comparison of the two routes, see should I wait for an NHS health check or book private screening today.
What Happens if a Marker Is Elevated?
- Clinical review: A GMC-registered doctor discusses the result in context – symptoms, family history and other blood work.
- Repeat test: A mildly raised marker is often repeated after 4–6 weeks to check the trend.
- Imaging: Ultrasound, CT or MRI may be arranged to investigate further.
- Specialist referral: If imaging is concerning, your screening doctor can write to your GP recommending an urgent referral. Your GP can then arrange an NHS two-week-wait pathway appointment, or a private specialist referral can be facilitated directly.
An elevated marker can be alarming, but the vast majority of raised results are caused by benign conditions. Screening simply ensures nothing is overlooked. For more detail on the clinical pathway, see our guides to when abnormal results should trigger further tests and the importance of follow-up consultations.
Frequently Asked Questions
Do I need to fast before tumour-marker blood tests?
Most tumour markers do not require fasting. However, if your screening also includes fasting glucose or a lipid panel, you will be asked to fast for 8–12 hours. Our guide to common screening mistakes covers preparation tips in detail. Your clinic will confirm preparation instructions when you book.
Can a normal tumour-marker result guarantee I don’t have cancer?
No. Some cancers do not produce detectable markers, and early-stage tumours may not raise levels above the reference range. Markers are one layer of screening and are most powerful when combined with clinical assessment and imaging.
How often should tumour markers be checked?
For general screening, annually or every two years is reasonable for adults over 40 or those with risk factors. Your doctor may recommend more frequent monitoring if a marker was previously borderline.
Are newer multi-cancer early detection (MCED) tests available privately?
MCED blood tests (such as Galleri) are being trialled in the UK via NHS England. Some private clinics offer them, but they are not yet part of standard screening guidelines. Your doctor can advise whether an MCED test adds value to your panel.
Why Trust Health Screening Clinic?
Our content is developed by medically trained writers and reviewed by practising clinicians to ensure accuracy and compliance with UK healthcare standards.
- ✓CQC-registered clinic with UKAS-accredited laboratory partners
- ✓GMC-registered doctors oversee all tumour-marker panels
- ✓Content reviewed against NICE, Cancer Research UK and PHE guidelines
- ✓ASA/CAP-compliant – no claims that screening diagnoses or prevents cancer
Informed Screening for Greater Awareness
Our cancer-risk screening packages include a range of tumour markers – from PSA or CA-125 in standard packages to CEA, AFP and CA 19-9 in advanced and platinum tiers – alongside a full blood count and liver function panel, all reviewed by a GMC-registered doctor.
View Screening PackagesThe information provided in this blog is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any health concerns.
